CSRT.L Regulatory News (CSRT)

News Release

29 January 2015

Consort Medical plc invests £2.2m in Atlas Genetics Series C Funding

Funding to accelerate global launch of Atlas io® molecular testing system

Hemel Hempstead, UK, January 29, 2015 - Consort Medical plc (LSE: CSRT) ("Consort", "Consort Medical" or the "Group"), a leading, global single source drug and delivery company, today announces that it has subscribed for a further investment of £2.2m in Atlas Genetics Ltd ("Atlas"). The investment forms part of the total £12.7m Series C funding announced today by Atlas.

Consort's subscription is proportionate to its existing 17.3% shareholding in Atlas (15.2% on a fully diluted basis). Following the Series C funding, Consort will have invested a total of £6.3m in Atlas.

Atlas develops ultra-rapid point-of-care diagnostic tests for infectious diseases. Atlas' io® system is at an advanced stage of development and is expected to be launched in Europe with a test for Chlamydia later this year. The Series C investment will be used to accelerate the launch of the io® system, initiate US clinical trials, and expand the menu of tests available initially in the sexually transmitted infections (STI) and hospital acquired infections (HAI) markets.

Bespak has a multi-year exclusive development and supply agreement with Atlas for the diagnostic test cartridges, and in June 2014 announced the completion of the manufacturing line for Atlas. Validation processes on the cartridge and manufacturing line are at an advanced stage.

Jonathan Glenn, Consort Medical's Chief Executive Officer commented:

"Consort Medical is at the leading edge of innovation and we are committed to investing in the development of new treatments, new markets and new opportunities.

"We are delighted that Atlas is now at a stage close to the launch of the io® system and we are excited about the company's near-term potential for growth with this rapid testing technology. We are pleased to partner with Atlas both in development and manufacturing services through Bespak, and in funding through Consort."

-Ends-

Enquiries:

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Our businesses

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). To learn more about our company visit our website at www.consortmedical.com.